Targeted Gene Insertion Needs More Than One Tool

By David Wiley, Director, Nucleic Acid Technology

Large gene insertion is rapidly emerging as a critical frontier in genomic medicine, but successfully delivering full-length functional genes or cellular receptors requires moving beyond a single standard editor. Every therapeutic application carries distinct biological and operational requirements—such as payload size, delivery vector constraints, tissue accessibility, and insertion site specificity. Single-tool solutions often force developers to compromise on editing efficiency or safety profiles.

Deploying a diverse toolkit containing complementary technologies, including large serine recombinases, retrotransposons, and CRISPR-guided systems, allows developers to tailor the insertion approach to the specific disease target and delivery context. Augmenting natural enzyme families through generative AI, active learning, and rational design opens up broad design space to engineer site-specific precision. Accessing multiple editing modalities ensures genomic medicine developers can match the precise technology to their therapeutic goal, optimizing potency and safety without forcing the disease target to fit a restricted tool set.